Press Release 2008

Press Release 2008

Results of a randomized, double-blind, placebo-controlled study of 46 overweight men and women revealed that participants receiving LeanGard® - a proprietary blend of three of Sabinsa's patented, clinically researched ingredients, ForsLean®, GarCitrin® and BioPerine® - had greater overall weight loss and reduction in body fat, as well as significant increases in lean body mass, than the placebo group.

The 12-week study, which was conducted at the Shifaa Hospital in Banglore, India, evaluated the efficacy and safety of LeanGard® as a dietary intervention for weight management support against a neutral placebo. Study participan ts were given either 500 mg of LeanGard or a placebo twice daily and screening visits were conducted on day zero, as well as at weeks three, six, nine and 12, to measure Total Body Water (TBW), Basal Metabolic Rate (BMR), Body Mass Index (BMI), Waist to Hip Ratio (WHR), Body Fat Percentage (BF%) and Lean Body Mass (LBM). Nineteen of the 21 LeanGard receiving participants achieved more than a 5 percent reduction in body weight at the end of 12 weeks. Additionally, the LeanGard® group showed a mean reduction in BMI of 7.45 percent from the baseline compared to 1.09 percent for the placebo group, as well as a decrease in body fat of 8.15 percent compared to 1.18 percent for the placebo group. A 4.36 percent increase in lean body mass was also seen in the LeanGard group versus a 0.67 percent increase from baseline in the placebo group. No clinically significant changes were observed in blood pressure or heart rate, hematological liver function, renal function, thyroid function, plasma lipid levels or other biochemical parameters.

"With nearly two-thirds of the world's population overweight, the need for effective products with extensive scientific validation is more important than ever," noted Dr. Lakshmi Prakash, vice president of innovation and business development, Sabinsa Corporation. "These study results indicate that LeanGard helps improve body composition and mitigate weight gain in overweight men and women with no apparent side effects."

LeanGard consists of a proprietary ratio of ForsLean, GarCitrin® and BioPerine®. ForsLean is an extract derived from Coleus forskohlii roots, and the only known plant source of forskolin, a natural compound that has been shown to increase lean body mass and help optimize body composition through cAMP activation. Garcitrin is a composition of calcium salt hydroxycitric acid (HCA) with garcinol, a polyisoprenylated benzophenone isolated from Garcinia cambogia and Garcinia indica fruits, which reduces fatty acid and lipid synthesis and improves lean body mass. GarCitrin®® is a standardized piperine composition derived from black pepper extract that has been shown to increase the absorption of nutrients in nutritional supplement formulations. All ingredients listed above are patented by Sabinsa for their use.

    VISIT US

  • Sabinsa Europe GmbH
    Monzastrasse 4
    63225 Langen
    Germany

  • +49 6103 270 11 11
  • +49 6103 270 11 27
  • info@sabinsa.eu

CERTIFICATES

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

CONTACT US

Disclaimer

Please note that this website and information provided herein is not for final consumers of a finished food, beverage, dietary supplement product or cosmetic product, as the information contained herein does not refer to finished products for consumers.

The information provided on the website is intended only for producers of finished food, beverage, dietary supplement and cosmetic product.

The statements related to ingredients on the website, have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.

The website and information herein are available in various countries across the world, and hence statements or product information including its classification may not be applicable in your country.

Information and statements provided on the website, shall not be construed as license to practice, or recommendations to infringe, any patents or other intellectual property rights of Sabinsa and others.

By browsing further, You understand the above terms.